Naomi Birbach is an associate in Goodwin’s IP Litigation group.  She joined the firm in 2013.

Ms. Birbach focuses her practice on intellectual property litigation in U.S. district courts and before the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) in post-grant proceedings such as inter partes reviews (IPRs). She has worked on cases involving pharmaceuticals, electronic devices, and display systems. Ms. Birbach has particular expertise in generic drug litigation under the Hatch-Waxman Act.

Ms. Birbach is also an editor of the firm’s biosimilars blog, Big Molecule Watch, which provides resources and observations through Goodwin’s active watch of legal, business and regulatory developments related to biologics, biosimilars and the Biologics Price Competition and Innovation Act (BPCIA).





Ms. Birbach has experience representing companies in all stages of patent litigation, from pre-suit investigation through trial and appeal. Some of her representative matters include:

  • Manufacturing Resources Int’l, Inc. v. Civiq Smartscapes, LLC et al. (D. Del.): Representing defendants against claims of patent infringement relating to digital outdoor displays.
  • Leviton Mfg. Co., Inc. v. Pass & Seymour, Inc.(E.D.N.Y): Representing defendant Pass & Seymour in a long-running dispute involving P&S’s core technology, ground-fault circuit interrupters (GFCIs), between the two market leaders in the U.S. GFCI market. 
  • Valeant et al. v. Actavis Laboratories, FL, Inc: (D.N.J.): Representing Actavis in a pending patent infringement action filed by Valeant, Salix, Wyeth, and Progenics under the Hatch-Waxman Act relating to Actavis’ filing of an abbreviated new drug application for a generic version of RELISTOR®.
  • Cosmo Technologies Ltd. et al. v. Actavis Laboratories FL, Inc. (D.Del): Represented Actavis in a patent infringement action filed by Cosmo and Valeant under the Hatch-Waxman Act relating to Actavis’s filing of an abbreviated new drug application for generic versions of Valeant’s drug UCERIS®. The District Court ruled at trial that Actavis’s product did not infringe the asserted patents.
  • Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.(D.N.J.): Represented Teva in a patent infringement action filed by Otsuka under the Hatch-Waxman Act relating to Teva’s filing of abbreviated new drug applications for generic versions of Otsuka’s drug ABILIFY®. Teva defeated a motion for a temporary restraining order, allowing Teva to launch its products. The case against Teva successfully settled before trial.
Professional Activities

Ms. Birbach is member of the New York Intellectual Property Law Association (NYIPLA).

Professional Experience

Prior to entering law school, Ms. Birbach was a patent examiner at the U.S. Patent and Trademark Office.

While attending law school, Ms. Birbach was an articles and notes editor of the American Criminal Law Review.


Ms. Birbach was named to The Best Lawyers in America 2021: Ones to Watch.

In The News









J.D., 2013
Georgetown University Law Center

(cum laude)

B.A., Chemistry, 2008
Cornell University



New York
New Jersey
U.S. Patent and Trademark Office (USPTO)


U.S. District Court for the Southern District of New York
U.S. District Court for the Eastern District of New York
U.S. Court of Appeals for the Federal Circuit
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique